We are live on ! Find out more
EI

EAM Investors Portfolio holdings

AUM $866M
1-Year Est. Return 377.14%
This Fund
S&P 500
This Quarter Est. Return
+1.43%
1 Year Est. Return
+377.14%
3 Year Est. Return
+5,228.32%
5 Year Est. Return
+49,813.17%
10 Year Est. Return
+19,957,666.26%
AUM
$632M
AUM Growth
-$223M
Cap. Flow
-$201M
Cap. Flow %
-31.75%
Top 10 Hldgs %
7.73%
Holding
416
New
106
Increased
49
Reduced
134
Closed
126

Top Buys

Rank Stock Value
1
LPCN icon
Lipocine
LPCN
+$4.68M
2
LGIH icon
LGI Homes
LGIH
+$4.16M
3
KFRC icon
Kforce
KFRC
+$4.03M
4
WIFI
Boingo Wireless, Inc.
WIFI
+$3.32M
5
EEFT icon
Euronet Worldwide
EEFT
+$3.3M

Sector Composition

Rank Sector Weight
1 Healthcare 27.59%
2 Technology 20.66%
3 Consumer Discretionary 13.6%
4 Industrials 10.33%
5 Financials 7.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LION
251
DELISTED
Fidelity Southern Corporation
LION
$1.06M 0.17%
+50,372
New +$972K
MTRX icon
252
Matrix Service
MTRX
$342M
$1.06M 0.17%
+47,198
New +$956K
DERM
253
DELISTED
Dermira, Inc.
DERM
$1.05M 0.17%
+45,172
New +$1.1M
OSIR
254
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$1.05M 0.17%
+56,694
New +$1.09M
WCIC
255
DELISTED
WCI Communities, Inc.
WCIC
$1.04M 0.16%
45,850
-3,035
-6% -$73K
EVC icon
256
Entravision Communication
EVC
$1.07B
$1.04M 0.16%
+156,021
New +$1.19M
SQBG
257
DELISTED
Sequential Brands Group, Inc.
SQBG
$1.03M 0.16%
1,785
+51
+3% +$33.4K
SCMP
258
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$1.03M 0.16%
+51,675
New +$1.18M
HRTX icon
259
Heron Therapeutics
HRTX
$96.8M
$1.02M 0.16%
41,700
-9,540
-19% -$318K
VYNT
260
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$1.02M 0.16%
866
+6
+0.7% +$9.19K
BCRX icon
261
BioCryst Pharmaceuticals
BCRX
$2.3B
$1.01M 0.16%
89,061
-27,908
-24% -$372K
MWW
262
DELISTED
Monster Worldwide Inc
MWW
$1.01M 0.16%
+157,795
New +$1.08M
EXTR icon
263
Extreme Networks
EXTR
$4.23B
$989K 0.16%
+294,432
New +$821K
FTK icon
264
Flotek Industries
FTK
$1.02B
$986K 0.16%
+9,841
New +$997K
COLL icon
265
Collegium Pharmaceutical
COLL
$1.16B
$969K 0.15%
+43,816
New +$792K
PGTI
266
DELISTED
PGT, Inc.
PGTI
$956K 0.15%
77,813
-26,122
-25% -$362K
RCKT icon
267
Rocket Pharmaceuticals
RCKT
$376M
$935K 0.15%
+24,857
New +$1.14M
CORI
268
DELISTED
Corium International, Inc.
CORI
$929K 0.15%
+99,340
New +$1.19M
AGRX
269
DELISTED
Agile Therapeutics
AGRX
$920K 0.15%
68
MB
270
DELISTED
MINDBODY, Inc. Class A Common Stock
MB
$920K 0.15%
+58,839
New +$777K
ANTH
271
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$917K 0.15%
18,812
+128
+0.7% +$8.94K
OME
272
DELISTED
Omega Protein
OME
$915K 0.14%
+53,891
New +$839K
CYNO
273
DELISTED
Cynosure, Inc. Class A
CYNO
$903K 0.14%
30,057
-12,668
-30% -$455K
MRTX
274
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$868K 0.14%
25,230
-13,524
-35% -$409K
CHGG icon
275
Chegg
CHGG
$115M
$861K 0.14%
119,415
-34,546
-22% -$273K

Similar funds

EAM Investors's Q3 2015 Portfolio in Review

As of Q3 2015, EAM Investors held 416 positions worth $632M, down 26% from $855M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.

EAM Investors withdrew a net $201M in Q3 2015, closing 126 positions and reducing 134 holdings. Its most notable exit was Sigma Designs Inc, an estimated $8.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 28% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, EAM Investors opened a new position in Lipocine worth $4.07M.

  • EAM Investors's largest Q3 2015 buy was Lipocine: 20,214 shares worth $4.07M.
  • EAM Investors added most to Boingo Wireless, Inc. in Q3 2015, an estimated $3.32M increase.
  • EAM Investors's biggest Q3 2015 reduction was NEOPHOTONICS CORP, cutting an estimated $4.34M.
  • EAM Investors fully exited Sigma Designs Inc in Q3 2015, selling an estimated $8.78M.
  • EAM Investors's ten largest holdings make up 7.7% of its $632M portfolio in Q3 2015.
  • EAM Investors opened 106 new positions and closed 126 in Q3 2015.
  • EAM Investors's portfolio value fell 26% quarter-over-quarter to $632M.

Based on EAM Investors's 13F filing for Q3 2015, filed 6 Nov 2015.